NYMXF NYMOX PHARMACEUTICAL CORP IFRS
In Vitro & In Vivo Diagnostic Substances · OTC · SEC CIK 1018735 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY—
TTM net income YoY49.2%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-701.3%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets1,135.9%
Debt / equity—
Current ratio0.09x
Interest coverage-18.95x
Cash quality & payout
Operating cash flow / net income0.58x
Accruals ratio-295.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 | FY20202020-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | $0 | $0 | $0 | $5,000 |
| Cost of revenue | — | $0 | $0 | $0 | $4,000 |
| Gross profit | — | $0 | $0 | $0 | $1,000 |
| R&D expense | $3.28M | $3.99M | $3.77M | $6.66M | $8.12M |
| SG&A expense | $1.00M | $4.36M | $2.88M | $5.85M | $3.60M |
| Operating income | -$4.28M | -$8.35M | -$6.65M | -$12.50M | -$11.72M |
| Interest expense | $226,000 | $58,000 | $28,000 | $20,000 | -$30,000 |
| Pretax income | -$4.49M | -$8.84M | -$6.58M | -$12.54M | -$11.74M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$4.49M | -$8.84M | -$6.58M | -$12.54M | -$11.74M |
| EPS (basic) | -0.05 | -0.10 | -0.07 | -0.15 | -0.16 |
| EPS (diluted) | — | — | — | — | -0.16 |
| Balance sheet | |||||
| Cash & equivalents | $74,000 | $70,000 | $1.40M | $830,000 | $3.61M |
| Receivables | $0 | $0 | $0 | $0 | $0 |
| Inventory | — | — | $0 | $34,000 | $34,000 |
| Current assets | $653,000 | $625,000 | $1.46M | $1.04M | $3.89M |
| PP&E, netmay include right-of-use assets (IFRS) | $1,000 | $2,000 | $10,000 | $22,000 | $28,000 |
| Total assets | $654,000 | $627,000 | $1.62M | $1.44M | $4.34M |
| Current liabilities | $7.43M | $3.80M | $2.11M | $1.79M | $1.97M |
| Total liabilities | $7.43M | $3.80M | $2.11M | $1.95M | $2.20M |
| Shareholders' equity | -$6.78M | -$3.17M | -$482,000 | -$506,000 | $2.15M |
| Shares outstanding | 94.54M | 93.54M | 90.52M | 85.55M | — |
| Cash flow statement | |||||
| Operating cash flow | -$2.60M | -$4.06M | -$5.21M | -$9.82M | -$10.04M |
| Capital expenditure | $0 | $3,000 | $0 | $6,000 | $13,000 |
| Free cash flow | -$2.60M | -$4.06M | -$5.21M | -$9.83M | -$10.05M |
| Investing cash flow | $0 | -$3,000 | $0 | -$6,000 | -$13,000 |
| Financing cash flow | $2.60M | $2.73M | $5.78M | $7.04M | $8.42M |
| Stock-based compensation | $671,000 | $3.36M | $593,000 | $2.60M | $1.75M |
Free plan shows the latest 5 periods; Pro shows all 10 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.